RET mutation
1 drugsPredictive biomarker for patient selection in 4 indications
1
Approved Drugs
4
Indications
1
Companies
RET mutation is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 4 indications including Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Thyroid Cancer. Explore the targeted therapies, indications, testing methods, and companies developing RET mutation drugs below.
Search RET mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting RET mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| RETEVMO | Eli Lilly | Oncology |